| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Departments of Internal Medicine and Pharmacology, Department of Veterans Affairs Medical Center and University of Iowa Carver College of Medicine, Iowa City, Iowa 52242; 2Department of Morphological Brain Science, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan; 3Department of Pediatrics, Philipps University Marburg, D-35032 Marburg, Germany; and 4Department of Neuroscience, Karolinska Institute, S-17177 Stockholm, Sweden
Submitted 23 June 2004 ; accepted in final form 29 July 2004
Induction of cyclooxygenase-2 (COX-2) in the renal pelvic wall increases prostaglandin E2 (PGE2) leading to stimulation of cAMP production, which results in substance P (SP) release and activation of renal mechanosensory nerves. The subtype of PGE receptors involved, EP2 and/or EP4, was studied by immunohistochemistry and renal pelvic administration of agonists and antagonists of EP2 and EP4 receptors. EP4 receptor-like immunoreactivity (LI) was colocalized with calcitonin gene-related peptide (CGRP)-LI in dorsal root ganglia (DRGs) at Th9-L1 and in nerve terminals in the renal pelvic wall. Th9-L1 DRG neurons also contained EP3 receptor-LI and COX-2-LI, each of which was colocalized with CGRP-LI in some neurons. No renal pelvic nerves contained EP3 receptor-LI and only very few nerves COX-2-LI. The EP1/EP2 receptor antagonist AH-6809 (20 µM) had no effect on SP release produced by PGE2 (0.14 µM) from an isolated rat renal pelvic wall preparation. However, the EP4 receptor antagonist L-161,982 (10 µM) blocked the SP release produced by the EP2/EP4 receptor agonist butaprost (10 µM) 12 ± 2 vs. 2 ± 1 and PGE2, 9 ± 1 vs. 1 ± 0 pg/min. The SP release by butaprost and PGE2 was similarly blocked by the EP4 receptor antagonist AH-23848 (30 µM). In anesthetized rats, the afferent renal nerve activity (ARNA) responses to butaprost 700 ± 100 and PGE2·780 ± 100%·s (area under the curve of ARNA vs. time) were unaffected by renal pelvic perfusion with AH-6809. However, 1 µM L-161,982 and 10 µM AH-23848 blocked the ARNA responses to butaprost by 94 ± 5 and 78 ± 10%, respectively, and to PGE2 by 74 ± 16 and 74 ± 11%, respectively. L-161,982 also blocked the ARNA response to increasing renal pelvic pressure 10 mmHg, 85 ± 5%. In conclusion, PGE2 increases renal pelvic release of SP and ARNA by activating EP4 receptors on renal sensory nerve fibers.
EP3 receptors; cyclooxygenase-2; substance P; butaprost; L-161,982
This article has been cited by other articles:
|
|
 |
|
  U. C. Kopp, M. Z. Cicha, and M. A. Yorek Impaired responsiveness of renal sensory nerves in streptozotocin-treated rats and obese Zucker diabetic fatty rats: role of angiotensin Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R858 - R866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. C. Kopp, M. Z. Cicha, L. A. Smith, J. Mulder, and T. Hokfelt Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of {alpha}1- and {alpha}2-adrenoceptors on renal sensory nerve fibers Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1561 - R1572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. C. Kopp, M. Z. Cicha, and L. A. Smith Differential effects of endothelin on activation of renal mechanosensory nerves: stimulatory in high-sodium diet and inhibitory in low-sodium diet Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2006; 291(5): R1545 - R1556. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
